

Thursday 10 March 2011

	Pearl A	Pearl D	Azzurea
14:30	<p>15. ARRHYTHMIAS: THE MORE YOU LOOK, THE MORE YOU FIND!! THE YIELD OF DIFFERENT MONITORING TECHNIQUES</p> <p>Co-chairmen: Elie Salamé (Lebanon) – Wajdi Haddad (Lebanon)</p> <p>What can Holter monitoring add to the risk stratification of sudden cardiac death? Ali Oto (Turkey)</p> <p>Implantable loop recorder in the management of syncope Jean-Claude Deharo (France)</p> <p>Prevention of stroke by continuous AF monitoring Oussama Wazni (USA)</p> <p>Is there a benefit of treating asymptomatic AF? Gerhard Hindricks (Germany)</p>	<p>16. HOW TO MANAGE ARRHYTHMIA IN PATIENTS WITH HF</p> <p>Co-chairmen: Antoine Kossaifi (Lebanon) – Jacques Mansourati (France)</p> <p>Heart failure and AF: did we find the link? Luc Jordaens (The Netherlands)</p> <p>Antiarrhythmic drugs in heart failure: what works and what does not? Charles Jazra (Lebanon)</p> <p>Anti arrhythmics versus ablation of AF in heart failure Johannes Brachmann (Germany)</p> <p>Management of VT In the acute setting of myocardial infarction Athanasios Manolis (Greece)</p> <p>CRT in atrial fibrillation: Does it work? Nazem Akoum (USA)</p>	<p>17. ANGIOTENSIN CONVERTING ENZYME INHIBITORS: NEW DATA</p> <p>Chairman: Rabih Azar (Lebanon)</p> <p>What have we learned on ACEI after more than 30 years? Faiez Zannad (France)</p> <p>Benefit of ACE inhibitors beyond BP reduction: anti-atherosclerotic effect and its implications Guiseppe Rosano (Italy)</p> <p>Benefits of the Perindopril-Amlodipine combination in patients with hypertension and/or CAD: evidence on efficacy and vascular protection Jean-Jacques Mourad (France)</p> <p>Made possible thanks to a grant from Servier</p>
16:00	<p>COFFEE BREAK</p>	<p>COFFEE BREAK</p>	<p>COFFEE BREAK</p>
16:30	<p>18. ARE WE GOING TOWARDS BETTER VASCULAR PROTECTION IN THE DIABETIC PATIENT?</p> <p>Co-chairmen: Jean-Charles Fruchart (France) Charles Jazra (Lebanon)</p> <p>The link between atherogenic dyslipidemia and vascular residual risk Gerd Assmann (Germany)</p> <p>Vascular protection in T2 diabetic patients; where do we stand now? Jean-Charles Fruchart (France)</p> <p>REALIST, the Middle East data Khaled Rubean (KSA)</p> <p>How to combine drug therapy to fight residual risk? Alberto Zamboni (Italy)</p> <p>A symposium of the residual risk reduction initiative (R³)</p>	<p>19. PREVENTIVE CRT AND ICD</p> <p>Co-chairmen: Nazih Kadri (Jordan) – Johnny Abboud (Lebanon)</p> <p>CRT to prevent disease progression in NYHA I-II patients Jean-Claude Daubert (France)</p> <p>Atrial fibrillation and CRT-CRTD: which relationship? Massimo Santini (Italy)</p> <p>CRT for lone LBBB Jean-Claude Deharo (France)</p> <p>CRT and ventricular arrhythmia prevention Dany Sayad (USA)</p> <p>ICD (Emerging indication for primary prevention) Athanasios Manolis (Greece)</p>	<p>20. CHANGING STRATEGIES IN THE MANAGEMENT OF ACS INTERACTIVE SESSION</p> <p>Co-chairmen: Leslie Cho (USA) – Mohammad Sobhi (Egypt)</p> <p>A case of severe chest pain with normal ECG and negative troponin? Ziyad Ghazzal (Lebanon)</p> <p>A case of clopidogrel resistance in the cath lab Rabih Azar (Lebanon)</p> <p>A case of revascularization of a STEMI Omar Hamaoui (Lebanon)</p> <p>From evidence to guidelines Khalifé Khalifé (France)</p> <p>Observed cases of STEMI patients in North Lebanon Abdel Karim Nagib (Lebanon)</p> <p>Made possible thanks to a grant from Eli Lilly</p>
18:30	<p>COFFEE BREAK</p>	<p>BREAK</p>	<p>BREAK</p>
18:45	<p>21. NOVARTIS SYMPOSIUM</p> <p>Co-chairmen: Assaad Maalouf (Lebanon) – Samir Mallat (Lebanon)</p> <p>Inhibition of the renin activities. New perspectives Xavier Girerd (France)</p> <p>The role of combination therapy in hypertension management Björn Dahlöf (Sweden)</p>	<p>BREAK</p>	<p>BREAK</p>
20:00	<p>BREAK</p>	<p>BREAK</p>	<p>BREAK</p>